3 December 2025 @ 5:00 pm – 6:00 pm
Our 5th UK Annual PALB2 formation Session is designed for people of all genders who carry a PALB2 gene mutation and would like to learn more about the gene and its implications.
The session will cover the latest research (including updates related to pancreatic cancer), current UK guidelines for PALB2 risk management, emerging treatment options, emotional wellbeing, and sources of support for carriers and their families.
Although our expert panel is UK-based and the primary focus is on UK guidance, everyone is welcome to attend. Age 16+.
SESSION DETAILS
The meeting will be on Teams – please use the link below:
Time: 3 December 2025 17:00-18:00 GMT (London)
Microsoft Teams Need help?
Meeting ID: 326 178 981 803 13
Passcode: AW6Dh6YF
Agenda – Expert Panel Discussion & Q&A
(facilitated by Yulia Baynham)
PALB2 gene: latest research and risk-management guidance
Professor Marc Tischkowitz and Dr Anju Kulkarni
Pancreatic cancer risks and surveillance
Dr Michael Chapman
Q&A session, including questions submitted in advance and live questions from participants
Yulia Baynham, PALB2 carrier
Panellists:
| Professor Marc Tischkowitz is a Consultant Clinical Geneticist and Lead for the Cancer Genetics service in East Anglia. He trained in Medical Oncology and Medical Genetics before moving to Canada, where he was in the Faculty at McGill University for six years before coming to Cambridge in 2011. Much of his research has been on the PALB2 and hereditary breast cancer predisposition but his interests cover all areas of hereditary cancer and translating the recent advances in genomic technology into clinical practice. He is a founding member of the Global PALB2 Interest Group. | |
| Dr Michael Chapman is Consultant Gastroenterologist, University College Hospital, London, where he also runs the EUROPAC clinic. Dr Chapman qualified in 1997 from UCL Medical School and completed specialist training in London. His practice includes general gastroenterology with a specialist interest in pancreatobiliary medicine and hepatology. Conditions of particular interest include primary sclerosing cholangitis, IgG4 related cholangitis and pancreatitis, gallstones, chronic pancreatitis, hereditary pancreatitis, duodenal polyps, pancreatic cancer and cholangiocarcinoma. | |
| Dr Anju Kulkarni is a Consultant Clinical Geneticist and Lead for the Cancer Genetics service at Guy’s and St Thomas’ NHS Foundation Trust. She graduated from Imperial College School of Medicine and trained at specialist level in both Medical Oncology and Clinical Genetics. Anju leads multidisciplinary specialist clinics for BRCA1/2 gene mutation carriers and rarer hereditary cancer conditions (including PALB2). She holds several regional and national roles, including council member of the UK Cancer Genetics Group and medical advisor to the UK Genetic Counselling Registration Board. | |
| Dr Vishakha Tripathi is a Consultant Genetic Counsellor at Guy’s and St Thomas’ NHS Foundation Trust. She has varied background ranging from special needs teaching, medicine and genetic counselling. She currently leads the hereditary breast and ovarian cancer service (HBOC) at Guy’s and through this work contributes to research in all areas of cancer genetics. Nationally, Vishakha has been Chair of the Genetic Counsellor Registration Board (GCRB) and is a member of the Clinical Genetics, Clinical Reference Group for NHS England. She also leads a successful cancer genetics course which has trained numerous family history nurses and clinicians in cancer care. (Standing member of the panel, advance Q&A responses) |
Previous sessions/ reference documents
T